{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:25:34Z","timestamp":1792027534664,"version":"4.4.0"},"reference-count":123,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T00:00:00Z","timestamp":1624233600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.bone.2021.116064","type":"journal-article","created":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T23:13:57Z","timestamp":1623971637000},"page":"116064","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"special_numbering":"C","title":["Challenges in the management of tumor-induced osteomalacia (TIO)"],"prefix":"10.1016","volume":"152","author":[{"given":"Maria Luisa","family":"Brandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin P.R.","family":"Clunie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Houillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne M.","family":"Jan de Beur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Minisola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Oheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lothar","family":"Seefried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2021.116064_bb0005","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S8756-3282(00)00334-3","article-title":"Tumor-induced osteomalacia and the regulation of phosphate homeostasis","volume":"27","author":"Kumar","year":"2000","journal-title":"Bone."},{"key":"10.1016\/j.bone.2021.116064_bb0010","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1073\/pnas.101545198","article-title":"Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia","volume":"98","author":"Shimada","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bone.2021.116064_bb0015","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1359\/jbmr.2002.17.6.1102","article-title":"Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism","volume":"17","author":"Jan de Beur","year":"2002","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.116064_bb0020","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1530\/ERC-11-0006","article-title":"Tumor-induced osteomalacia","volume":"18","author":"Chong","year":"2011","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.bone.2021.116064_bb0025","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.bonr.2017.09.002","article-title":"Tumor-induced osteomalacia","volume":"7","author":"Florenzano","year":"2017","journal-title":"Bone Rep."},{"key":"10.1016\/j.bone.2021.116064_bb0030","doi-asserted-by":"crossref","first-page":"17044","DOI":"10.1038\/nrdp.2017.44","article-title":"Tumour-induced osteomalacia","volume":"3","author":"Minisola","year":"2017","journal-title":"Nat. Rev. Dis. Primers."},{"key":"10.1016\/j.bone.2021.116064_bb0035","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s00223-020-00691-6","article-title":"Tumor-induced osteomalacia","volume":"108","author":"Florenzano","year":"2021","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2021.116064_bb0040","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1507\/endocrj.EJ15-0275","article-title":"Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment","volume":"62","author":"Endo","year":"2015","journal-title":"Endocr. J."},{"key":"10.1016\/j.bone.2021.116064_bb0045","doi-asserted-by":"crossref","DOI":"10.1007\/s00223-021-00843-2","article-title":"Epidemiology of tumor-induced osteomalacia in Denmark","author":"Abrahamsen","year":"2021","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2021.116064_bb0055","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/jbmr.2079","article-title":"Increased osteopontin contributes to inhibition of bone mineralization in FGF23-deficient mice","volume":"29","author":"Yuan","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.116064_bb0060","first-page":"229","article-title":"FGF23 promotes renal calcium reabsorption through the TRPV5 channel","volume":"33","author":"Andrukhova","year":"2014","journal-title":"EMBO J."},{"key":"10.1016\/j.bone.2021.116064_bb0080","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S2213-8587(19)30426-7","article-title":"Approach to patients with hypophosphataemia","volume":"8","author":"Florenzano","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.bone.2021.116064_bb0085","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s40618-018-0849-5","article-title":"Phosphaturic mesenchymal tumors: what an endocrinologist should know","volume":"41","author":"Boland","year":"2018","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.bone.2021.116064_bb0090","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1007\/s00467-012-2175-z","article-title":"Phosphate homeostasis and its role in bone health","volume":"27","author":"Goretti Penido","year":"2012","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.bone.2021.116064_bb0095","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/bjaed\/mkw012","article-title":"Physiology of oxygen transport","volume":"16","author":"Dunn","year":"2016","journal-title":"BJA Educ."},{"key":"10.1016\/j.bone.2021.116064_bb0100","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/ki.2008.355","article-title":"Renal phosphate wasting due to tumor-induced osteomalacia: a frequently delayed diagnosis","volume":"76","author":"Gore","year":"2009","journal-title":"Kidney Int."},{"key":"10.1016\/j.bone.2021.116064_bb0105","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11154-015-9318-z","article-title":"The PTH-vitamin D-FGF23 axis","volume":"16","author":"Blau","year":"2015","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.bone.2021.116064_bb0110","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1152\/physrev.00002.2011","article-title":"Regulation and function of the FGF23\/klotho endocrine pathways","volume":"92","author":"Martin","year":"2012","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.bone.2021.116064_bb0115","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3389\/fphys.2019.00304","article-title":"The EPO-FGF23 signaling pathway in erythroid progenitor cells: opening a new area of research","volume":"10","author":"van Vuren","year":"2019","journal-title":"Front. Physiol."},{"key":"10.1016\/j.bone.2021.116064_bb0120","doi-asserted-by":"crossref","first-page":"F132","DOI":"10.1152\/ajprenal.00081.2017","article-title":"Acute blood loss stimulates fibroblast growth factor 23 production","volume":"314","author":"Rabadi","year":"2018","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.bone.2021.116064_bb0125","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.kint.2017.11.018","article-title":"Erythropoietin induces bone marrow and plasma fibroblast growth factor 23 during acute kidney injury","volume":"93","author":"Toro","year":"2018","journal-title":"Kidney Int."},{"key":"10.1016\/j.bone.2021.116064_bb0130","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/01.mnh.0000447020.74593.6f","article-title":"Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease","volume":"23","author":"Wolf","year":"2014","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1016\/j.bone.2021.116064_bb0135","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1681\/ASN.2007010068","article-title":"How fibroblast growth factor 23 works","volume":"18","author":"Liu","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.bone.2021.116064_bb0140","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.1074\/jbc.C500457200","article-title":"Regulation of fibroblast growth factor-23 signaling by klotho","volume":"281","author":"Kurosu","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2021.116064_bb0145","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrendo.2009.196","article-title":"The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis","volume":"5","author":"Razzaque","year":"2009","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.bone.2021.116064_bb0150","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/nature05315","article-title":"Klotho converts canonical FGF receptor into a specific receptor for FGF23","volume":"444","author":"Urakawa","year":"2006","journal-title":"Nature."},{"key":"10.1016\/j.bone.2021.116064_bb0155","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1359\/JBMR.0301264","article-title":"FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis","volume":"19","author":"Shimada","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.116064_bb0160","doi-asserted-by":"crossref","first-page":"5372","DOI":"10.1073\/pnas.95.9.5372","article-title":"Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities","volume":"95","author":"Beck","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bone.2021.116064_bb0165","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a031260","article-title":"Biology of fibroblast growth factor 23: from physiology to pathology","volume":"8","author":"Courbebaisse","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.bone.2021.116064_bb0170","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/1097-0142(19870415)59:8<1442::AID-CNCR2820590810>3.0.CO;2-Q","article-title":"Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets","volume":"59","author":"Weidner","year":"1987","journal-title":"Cancer."},{"key":"10.1016\/j.bone.2021.116064_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00000478-200401000-00001","article-title":"Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature","volume":"28","author":"Folpe","year":"2004","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.bone.2021.116064_bb0180","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1210\/jc.2011-1757","article-title":"The importance of whole body imaging in tumor-induced osteomalacia","volume":"96","author":"Chong","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2021.116064_bb0185","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/jbmr.1642","article-title":"Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: report of 39 cases and review of the literature","volume":"27","author":"Jiang","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.116064_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00132-019-03719-4","article-title":"Tumor-induced osteomalacia caused by an FGF23-secreting myopericytoma\u202f: case report and literature review","volume":"49","author":"Muro Bushart","year":"2020","journal-title":"Orthopade."},{"key":"10.1016\/j.bone.2021.116064_bb0195","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/PAS.0000000000000290","article-title":"A novel chromogenic in situ hybridization assay for FGF23 mRNA in phosphaturic mesenchymal tumors","volume":"39","author":"Carter","year":"2015","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.bone.2021.116064_bb0200","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/his.13377","article-title":"Histopathological and genetic review of phosphaturic mesenchymal tumours, mixed connective tissue variant","volume":"72","author":"Yamada","year":"2018","journal-title":"Histopathology."},{"key":"10.1016\/j.bone.2021.116064_bb0205","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/modpathol.2016.137","article-title":"Characterization of FN1-FGFR1 and novel FN1-FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors","volume":"29","author":"Lee","year":"2016","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bone.2021.116064_bb0210","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/path.4465","article-title":"Identification of a novel FN1-FGFR1 genetic fusion as a frequent event in phosphaturic mesenchymal tumour","volume":"235","author":"Lee","year":"2015","journal-title":"J. Pathol."},{"key":"10.1016\/j.bone.2021.116064_bb0215","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/jbmr.1810","article-title":"Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets","volume":"28","author":"W\u00f6hrle","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.116064_bb0220","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1297\/cpe.29.69","article-title":"Malignant transformation of phosphaturic mesenchymal tumor: a case report and literature review","volume":"29","author":"Oyama","year":"2020","journal-title":"Clin. Pediatr. Endocrinol."},{"key":"10.1016\/j.bone.2021.116064_bb0225","article-title":"Distant lung metastases caused by a histologically benign phosphaturic mesenchymal tumor","volume":"2018","author":"Yavropoulou","year":"2018","journal-title":"Endocrinol. Diabetes Metab. Case Rep."},{"key":"10.1016\/j.bone.2021.116064_bb0230","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1210\/jc.2015-3854","article-title":"Needle(s) in the haystack-synchronous multifocal tumor-induced osteomalacia","volume":"101","author":"Annamalai","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2021.116064_bb0235","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1210\/jc.2012-3473","article-title":"Oncogenic osteomalacia due to FGF23-expressing colon adenocarcinoma","volume":"98","author":"Leaf","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2021.116064_bb0240","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1210\/jc.2014-2120","article-title":"Ovarian cancer-related hypophosphatemic osteomalacia--a case report","volume":"99","author":"Lin","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2021.116064_bb0245","first-page":"2195","article-title":"Advanced prostate cancer as a cause of oncogenic osteomalacia: an underdiagnosed condition","volume":"20","author":"Mak","year":"2012","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.bone.2021.116064_bb0250","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s40200-019-00398-y","article-title":"Oncogenic osteomalacia and metastatic breast cancer: a case report and review of the literature","volume":"18","author":"Savva","year":"2019","journal-title":"J. Diabetes Metab. Disord."},{"key":"10.1016\/j.bone.2021.116064_bb0255","doi-asserted-by":"crossref","DOI":"10.1515\/jpem-2020-0079","article-title":"Tumor-induced rickets-osteomalacia: an enigma","author":"Kumar","year":"2020","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2021.116064_bb0260","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/BPB.0b013e32832f59cb","article-title":"A 9-month-old phosphaturic mesenchymal tumor mimicking the intractable rickets","volume":"19","author":"Jung","year":"2010","journal-title":"J. Pediatr. Orthop. B"},{"key":"10.1016\/j.bone.2021.116064_bb0265","article-title":"Phosphaturic mesenchymal tumors among elderly patients: a case report and review of literature","volume":"2019","author":"Adnan","year":"2019","journal-title":"Endocrinol. Diabetes Metab. Case Rep."},{"key":"10.1016\/j.bone.2021.116064_bb0270","doi-asserted-by":"crossref","first-page":"K1","DOI":"10.1530\/EJE-13-0581","article-title":"Six-year follow-up of a characteristic osteolytic lesion in a patient with tumor-induced osteomalacia","volume":"170","author":"Piemonte","year":"2014","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.bone.2021.116064_bb0275","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1507\/endocrj.EJ16-0587","article-title":"The diagnostic dilemma of tumor induced osteomalacia: a retrospective analysis of 144 cases","volume":"64","author":"Feng","year":"2017","journal-title":"Endocr. J."},{"key":"10.1016\/j.bone.2021.116064_bb0280","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1530\/EC-19-0341","article-title":"Tumor induced osteomalacia in head and neck region: single center experience and systematic review","volume":"8","author":"Shah","year":"2019","journal-title":"Endocr. Connect."},{"key":"10.1016\/j.bone.2021.116064_bb0285","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1186\/s12891-017-1756-1","article-title":"Treatment and outcomes of tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors: retrospective review of 12 patients","volume":"18","author":"Zuo","year":"2017","journal-title":"BMC Musculoskelet. Disord."},{"key":"10.1016\/j.bone.2021.116064_bb0290","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jama.294.10.1260","article-title":"Tumor-induced osteomalacia","volume":"294","author":"Jan de Beur","year":"2005","journal-title":"JAMA."},{"key":"10.1016\/j.bone.2021.116064_bb0295","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/SMJ.0b013e31821427db","article-title":"Tumor-induced osteomalacia (TIO): atypical presentation","volume":"104","author":"Khaliq","year":"2011","journal-title":"South. Med. J."},{"key":"10.1016\/j.bone.2021.116064_bb0300","first-page":"427","article-title":"Clinical and immunohistopathologic study of phosphaturic mesenchymal tumor","volume":"47","author":"Li","year":"2018","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"10.1016\/j.bone.2021.116064_bb0305","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1093\/rheumatology\/39.12.1415","article-title":"Four cases of acquired hypophosphataemic (\u2019oncogenic\u2019) osteomalacia. Problems of diagnosis, treatment and long-term management","volume":"39","author":"Clunie","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.bone.2021.116064_bb0310","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1172\/JCI113172","article-title":"Dietary intake of phosphorus modulates the circadian rhythm in serum concentration of phosphorus. Implications for the renal production of 1,25-dihydroxyvitamin D","volume":"80","author":"Portale","year":"1987","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bone.2021.116064_bb0315","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1210\/jc.2011-1319","article-title":"Approach to the hypophosphatemic patient","volume":"97","author":"Imel","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2021.116064_bb0320","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/ckj\/sfw086","article-title":"Serum FGF23 levels may not be associated with serum phosphate and 1,25-dihydroxyvitamin D levels in patients with Fanconi syndrome-induced hypophosphatemia","volume":"9","author":"Goto","year":"2016","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.bone.2021.116064_bb0325","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11154-017-9408-1","article-title":"X-linked hypophosphatemia and growth","volume":"18","author":"Fuente","year":"2017","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.bone.2021.116064_bb0330","first-page":"17","article-title":"FGF23 and associated disorders of phosphate wasting","volume":"17","author":"Gohil","year":"2019","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"10.1016\/j.bone.2021.116064_bb0335","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1210\/er.2017-00220","article-title":"X-linked hypophosphatemia and FGF23-related hypophosphatemic diseases: prospect for new treatment","volume":"39","author":"Kinoshita","year":"2018","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bone.2021.116064_bb0340","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/2042018816678363","article-title":"Long-term iron polymaltose infusions associated with hypophosphataemic osteomalacia: a report of two cases and review of the literature","volume":"8","author":"Bishay","year":"2017","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2021.116064_bb0345","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2147\/TCRM.S243462","article-title":"Hypophosphatemia associated with intravenous iron therapies for iron deficiency anemia: a systematic literature review","volume":"16","author":"Glaspy","year":"2020","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.bone.2021.116064_bb0350","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/jbmr.1923","article-title":"Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women","volume":"28","author":"Wolf","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.116064_bb0355","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41581-019-0189-5","article-title":"FGF23 at the crossroads of phosphate, iron economy and erythropoiesis","volume":"16","author":"Edmonston","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.bone.2021.116064_bb0360","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003975","article-title":"Parathyroid-specific deletion of Klotho unravels a novel calcineurin-dependent FGF23 signaling pathway that regulates PTH secretion","volume":"9","author":"Olauson","year":"2013","journal-title":"PLoS Genet."},{"key":"10.1016\/j.bone.2021.116064_bb0365","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/BF03343720","article-title":"Development of tertiary hyperparathyroidism after phosphate supplementation in oncogenic osteomalacia","volume":"23","author":"Huang","year":"2000","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.bone.2021.116064_bb0370","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/ng1905","article-title":"Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism","volume":"38","author":"Feng","year":"2006","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bone.2021.116064_bb0375","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ajhg.2010.01.010","article-title":"Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene","volume":"86","author":"Levy-Litan","year":"2010","journal-title":"Am. J. Hum. Genet."},{"issue":"Suppl. 4","key":"10.1016\/j.bone.2021.116064_bb0380","doi-asserted-by":"crossref","first-page":"iv45","DOI":"10.1093\/ndt\/gfu217","article-title":"Genetic diseases of renal phosphate handling","volume":"29","author":"Wagner","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.bone.2021.116064_bb0385","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1067\/j.cpradiol.2018.06.005","article-title":"Molecular imaging in diagnosis of tumor-induced osteomalacia","volume":"48","author":"Yang","year":"2019","journal-title":"Curr. Probl. Diagn. Radiol."},{"key":"10.1016\/j.bone.2021.116064_bb0390","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1097\/RLU.0000000000000460","article-title":"Comparison of 18F-FDG and 68Ga DOTATATE PET\/CT in localization of tumor causing oncogenic osteomalacia","volume":"40","author":"Agrawal","year":"2015","journal-title":"Clin. Nucl. Med."},{"key":"10.1016\/j.bone.2021.116064_bb0395","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2014.04.016","article-title":"68Ga DOTA-TATE PET\/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT\/CT","volume":"64","author":"Breer","year":"2014","journal-title":"Bone."},{"key":"10.1016\/j.bone.2021.116064_bb0400","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1210\/jc.2016-2052","article-title":"(68)Ga-DOTATATE for tumor localization in tumor-induced osteomalacia","volume":"101","author":"El-Maouche","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2021.116064_bb0405","article-title":"Diagnostic efficiency of (68)Ga-DOTANOC PET\/CT in patients with suspected tumour-induced osteomalacia","author":"He","year":"2020","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.bone.2021.116064_bb0410","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0140-6736(02)07846-7","article-title":"Localisation of mesenchymal tumours by somatostatin receptor imaging","volume":"359","author":"Jan de Beur","year":"2002","journal-title":"Lancet."},{"key":"10.1016\/j.bone.2021.116064_bb0415","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/MNM.0000000000001163","article-title":"Performance of 68Ga-DOTA-SST PET\/CT, octreoscan SPECT\/CT and 18F-FDG PET\/CT in the detection of culprit tumors causing osteomalacia: a meta-analysis","volume":"41","author":"Jiang","year":"2020","journal-title":"Nucl. Med. Commun."},{"key":"10.1016\/j.bone.2021.116064_bb0420","article-title":"Detection rate of culprit tumors causing osteomalacia using somatostatin receptor PET\/CT: systematic review and meta-analysis","volume":"10","author":"Meyer","year":"2019","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.bone.2021.116064_bb0425","first-page":"311","article-title":"Somatostatin receptor PET ligands - the next generation for clinical practice","volume":"8","author":"Pauwels","year":"2018","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.bone.2021.116064_bb0430","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/jbmr.1881","article-title":"Tumor localization and biochemical response to cure in tumor-induced osteomalacia","volume":"28","author":"Chong","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.116064_bb0435","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.clinimag.2019.04.007","article-title":"Tumor-induced osteomalacia - current imaging modalities and a systematic approach for tumor localization","volume":"56","author":"Rayamajhi","year":"2019","journal-title":"Clin. Imaging"},{"key":"10.1016\/j.bone.2021.116064_bb0440","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2967\/jnumed.116.180430","article-title":"Head-to-head comparison of (64)Cu-DOTATATE and (68)Ga-DOTATOC PET\/CT: a prospective study of 59 patients with neuroendocrine tumors","volume":"58","author":"Johnbeck","year":"2017","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bone.2021.116064_bb0445","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1210\/jc.2013-3980","article-title":"Diagnostic findings and treatment in a 51-year-old woman with oncogenic osteomalacia","volume":"99","author":"Lapa","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2021.116064_bb0450","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/jbmr.316","article-title":"Selective venous catheterization for the localization of phosphaturic mesenchymal tumors","volume":"26","author":"Andreopoulou","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.116064_bb0455","first-page":"5389","article-title":"Acquired hypophosphatemic osteomalacia is easily misdiagnosed or neglected by rheumatologists: a report of 9 cases","volume":"15","author":"Li","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.bone.2021.116064_bb0460","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1210\/jc.2006-2865","article-title":"Determination of the elimination half-life of fibroblast growth factor-23","volume":"92","author":"Khosravi","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2021.116064_bb0465","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12957-015-0763-7","article-title":"Tumour-induced osteomalacia: a literature review and a case report","volume":"14","author":"Dadoniene","year":"2016","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.bone.2021.116064_bb0470","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13000-016-0477-3","article-title":"Immunohistochemical and molecular detection of the expression of FGF23 in phosphaturic mesenchymal tumors including the non-phosphaturic variant","volume":"11","author":"Shiba","year":"2016","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.bone.2021.116064_bb0475","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMc070347","article-title":"Radiofrequency ablation of a tumor causing oncogenic osteomalacia","volume":"357","author":"Hesse","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2021.116064_bb0480","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s11926-015-0512-5","article-title":"Tumor-induced osteomalacia: an up-to-date review","volume":"17","author":"Hautmann","year":"2015","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.bone.2021.116064_bb0485","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa010839","article-title":"Octreotide therapy for tumor-induced osteomalacia","volume":"345","author":"Seufert","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2021.116064_bb0490","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1210\/js.2016-1088","article-title":"Peptide receptor radionuclide and octreotide: a novel approach for metastatic tumor-induced osteomalacia","volume":"1","author":"Nair","year":"2017","journal-title":"J. Endocr. Soc."},{"key":"10.1016\/j.bone.2021.116064_bb0495","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/jbmr.3162","article-title":"Octreotide is ineffective in treating tumor-induced osteomalacia: results of a short-term therapy","volume":"32","author":"Ovejero","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.116064_bb0500","author":"Ultragenyx"},{"key":"10.1016\/j.bone.2021.116064_bb0505","author":"CRYSVITA\u00ae (burosumab-twza)"},{"key":"10.1016\/j.bone.2021.116064_bb0510","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.4184","article-title":"Interim analysis of a phase 2 open-label trial assessing burosumab efficacy and safety in patients with tumor-induced osteomalacia","author":"Imanishi","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.116064_bb0515","article-title":"Burosumab for the treatment of tumor-induced osteomalacia","author":"Jan de Beur","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.116064_bb0520","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jbspin.2019.07.012","article-title":"Burosumab in tumor-induced osteomalacia: a case report","volume":"87","author":"Day","year":"2020","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.bone.2021.116064_bb0525","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/jbmr.3903","article-title":"Nonremission and recurrent tumor-induced osteomalacia: a retrospective study","volume":"35","author":"Li","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.116064_bb0530","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12891-015-0496-3","article-title":"Surgical treatment of tumor-induced osteomalacia: a retrospective review of 40 cases with extremity tumors","volume":"16","author":"Sun","year":"2015","journal-title":"BMC Musculoskelet. Disord."},{"key":"10.1016\/j.bone.2021.116064_bb0535","doi-asserted-by":"crossref","first-page":"e6750","DOI":"10.1097\/MD.0000000000006750","article-title":"Malignant phosphaturic mesenchymal tumor with pulmonary metastasis: a case report","volume":"96","author":"Qiu","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bone.2021.116064_bb0540","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12891-017-1446-z","article-title":"A rare case of multiple phosphaturic mesenchymal tumors along a tendon sheath inducing osteomalacia","volume":"18","author":"Arai","year":"2017","journal-title":"BMC Musculoskelet. Disord."},{"key":"10.1016\/j.bone.2021.116064_bb0545","doi-asserted-by":"crossref","first-page":"590","DOI":"10.4103\/ija.IJA_57_17","article-title":"Perioperative management of patients with severe hypophosphataemia secondary to oncogenic osteomalacia: our experience and review of literature","volume":"61","author":"Verma","year":"2017","journal-title":"Indian J. Anaesth."},{"key":"10.1016\/j.bone.2021.116064_bb0550","article-title":"Surgical treatment of recurrent spinal phosphaturic mesenchymal tumor-induced osteomalacia: a case report","volume":"99","author":"Liu","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bone.2021.116064_bb0555","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jocn.2019.01.010","article-title":"Spinal phosphaturic mesenchymal tumors: case report and literature review","volume":"63","author":"Wang","year":"2019","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.bone.2021.116064_bb0560","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00256-016-2548-7","article-title":"Successful CT guided cryoablation of phosphaturic mesenchymal tumor in the soft tissues causing tumor-induced osteomalacia: a case report","volume":"46","author":"Cowan","year":"2017","journal-title":"Skelet. Radiol."},{"key":"10.1016\/j.bone.2021.116064_bb0565","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1210\/jc.2013-4515","article-title":"Radiofrequency ablation, an effective modality of treatment in tumor-induced osteomalacia: a case series of three patients","volume":"99","author":"Jadhav","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2021.116064_bb0570","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10178","article-title":"Successful management of tumor-induced osteomalacia with radiofrequency ablation: a case series","volume":"3","author":"Mishra","year":"2019","journal-title":"JBMR Plus"},{"key":"10.1016\/j.bone.2021.116064_bb0575","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1002\/jbmr.3219","article-title":"Multimodality image-guided cryoablation for inoperable tumor-induced osteomalacia","volume":"32","author":"Tella","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.116064_bb0580","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1210\/jc.2012-1719","article-title":"Successful treatment of tumor-induced osteomalacia with CT-guided percutaneous ethanol and cryoablation","volume":"97","author":"Tutton","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2021.116064_bb0585","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/bcp.13763","article-title":"Pharmacological management of X-linked hypophosphataemia","volume":"85","author":"Imel","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bone.2021.116064_bb0590","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","article-title":"Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia","volume":"15","author":"Haffner","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.bone.2021.116064_bb0595","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1530\/EC-13-0103","article-title":"Therapeutic management of hypophosphatemic rickets from infancy to adulthood","volume":"3","author":"Linglart","year":"2014","journal-title":"Endocr. Connect."},{"key":"10.1016\/j.bone.2021.116064_bb0600","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1359\/jbmr.070304","article-title":"Cinacalcet in the management of tumor-induced osteomalacia","volume":"22","author":"Geller","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.116064_bb0605","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-228375","article-title":"Treating osteoporosis: a near miss in an unusual case of FGF-23 mediated bone loss","volume":"12","author":"Paul","year":"2019","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.bone.2021.116064_bb0610","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.bonr.2018.03.005","article-title":"Bone histomorphometry in the evaluation of osteomalacia","volume":"8","author":"Bhan","year":"2018","journal-title":"Bone Rep."},{"key":"10.1016\/j.bone.2021.116064_bb0615","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/qjmed\/hcq039","article-title":"Medication-induced hypophosphatemia: a review","volume":"103","author":"Liamis","year":"2010","journal-title":"QJM."},{"key":"10.1016\/j.bone.2021.116064_bb0620","article-title":"Response of tumor-induced osteomalacia (TIO) to the FGFR inhibitor BGJ398","volume":"34","author":"Brennan","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bone.2021.116064_bb0625","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1056\/NEJMc2020399","article-title":"Targeted FGFR blockade for the treatment of tumor-induced Osteomalacia","volume":"383","author":"Hartley","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2021.116064_bb0630","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.pcl.2018.09.002","article-title":"Fanconi syndrome","volume":"66","author":"Foreman","year":"2019","journal-title":"Pediatr. Clin. N. Am."},{"key":"10.1016\/j.bone.2021.116064_bb0635","series-title":"Fanconi Syndrome","author":"Keefe","year":"2020"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S875632822100226X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S875632822100226X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:42:28Z","timestamp":1762659748000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S875632822100226X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":123,"alternative-id":["S875632822100226X"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2021.116064","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges in the management of tumor-induced osteomalacia (TIO)","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2021.116064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116064"}}